Affibody Molecules: Structural Advantages and Application Prospects of Small Affinity Proteins in Precision Diagnostics and Therapy

Introduction

In biomedical research and clinical applications, antibodies have long been indispensable tools due to their high specificity. However, as large proteins (approximately 150 kDa), antibodies have limitations in certain applications, such as poor tissue penetration, high production costs, and the potential to trigger immunogenic reactions. Over the past three decades, a new class of small-molecule affinity proteins—Affibody molecules—has gradually come to the attention of researchers. Their unique structure and properties have opened up new possibilities in fields such as targeted therapy, molecular imaging, and biotechnology. This issue focuses on the structural advantages and application prospects of Affibodies.

1. Origin and Structural Basis of Affibodies

Affibody molecules are derived from the B domain of Staphylococcal protein A (SpA). Protein A is a surface protein of Staphylococcus aureus that can bind to the Fc region of immunoglobulin G (IgG); this property has been widely utilized in antibody purification. The B domain is a small domain composed of 58 amino acid residues with a molecular weight of approximately 6.5 kDa. Its core structure consists of three α-helix bundles, making it highly stable.

Through protein engineering, researchers modified the B domain into a “Z domain” and introduced random mutations at the 13 amino acid sites on its surface involved in binding, thereby constructing an affibody library with enormous capacity. Using techniques such as phage display, affinity molecules capable of binding any given target (such as receptors, enzymes, cytokines, etc.) with high affinity and specificity can be screened from the library.

图1 SpA基因及其辅助组分的示意图.png

Figure 1 Schematic diagram of the SpA gene and its accessory components

2. Core Advantages of Affibodies

Compared to traditional antibodies or their derivatives, affibody molecules possess a series of unique physicochemical and biological advantages, making them highly attractive engineered protein therapeutics and diagnostic tools:

(1) Small molecular size and strong tissue penetration: With a size of approximately 6.5 kDa, affibodies are significantly smaller than antibodies (approximately 150 kDa). This small size confers excellent tissue penetration, enabling them to infiltrate solid tumor tissues more effectively and rapidly reach target sites.

(2) Stable physicochemical properties and ease of production: The triple-helix bundle structure of affinity molecules confers them with extremely high thermal and chemical stability. Some affinity molecules can regain their binding capacity upon cooling to room temperature after being treated at high temperatures of 90°C. Furthermore, they can be produced in large quantities efficiently and cost-effectively in prokaryotic expression systems such as E. coli, or synthesized chemically, thereby avoiding complex mammalian cell culture processes.

(3) Rapid plasma clearance and high imaging contrast: In in vivo imaging applications, affinity molecules are rapidly cleared from the bloodstream and eliminated from non-target tissues, resulting in a higher signal-to-background ratio at the target site. This facilitates rapid, high-resolution imaging of lesions such as tumors.

(4) Low immunogenicity: Due to their small molecular weight and bacterial protein origin, affibodies typically exhibit low immunogenicity after engineering, making them safer for repeated administration.

图2 亲合体（Affibody）结构优势（与抗体相比）.png

Figure 2 Structural Advantages of Affibodies (Compared to Antibodies)

3. Application Prospects of Affibodies

(1) Molecular Imaging and Tumor Diagnosis: Affibody molecules can serve as molecular recognition tools in diagnostic and therapeutic applications. Numerous preclinical studies have reported on the diagnostic and therapeutic applications of these alternative scaffold molecules, and preliminary clinical evidence is now emerging, indicating that Affibody molecules are highly effective and safe in humans. Their small size and ease of engineering make Affibody molecules particularly well-suited for multispecific structures.

(2) Targeted Therapy: Affibodies can either act directly as antagonists to block the function of disease-causing proteins or serve as “warhead” delivery vehicles, precisely delivering cytotoxic drugs, radioisotopes, or nanoparticles to tumor sites to achieve targeted therapy.

(3) Multivalent Assembly: Monovalent affinity molecules are sometimes cleared too rapidly by the kidneys due to their low molecular weight. By engineering bivalent, trivalent, or multivalent affinity molecules (e.g., by fusing them to an albumin-binding domain), researchers can extend their half-life in the body and enhance their binding affinity.

(4) Supramolecular Assembly: A recent research trend involves using affinity molecules to construct more complex supramolecular structures. For example, multifunctional nanoplatforms can be prepared through pre-assembly (genetic fusion or chemical linking) or post-assembly (attaching affinity molecules to preformed scaffolds such as liposomes, polymer micelles, or inorganic nanoparticles) strategies to achieve integrated diagnosis and treatment (theranostics). For instance, when an EGFR-specific affinity ligand is conjugated to gold-silicon nanoparticles for surface-enhanced Raman scattering (SERS) imaging, the signal intensity in EGFR-positive tumors is nearly 35 times higher than in EGFR-negative tumors.

(5) Biotechnology: In basic research and biotechnology, affibodies serve as ideal alternatives to antibodies for protein affinity purification, capture molecules in biosensors, and detection reagents in assays such as Western blots and Elisas.

图3 Affibody分子多特异性结构（改造用于不同的诊疗场景）.png

Figure 3: Multispecific structure of affibody molecules (engineered for different diagnostic and therapeutic applications)

Summary

Affibody molecules represent a significant advancement in the fields of protein therapeutics and diagnostic reagents following the development of monoclonal antibodies. Their small size, high stability, ease of engineering, and rapid targeting capabilities give them tremendous potential for addressing current unmet clinical needs, such as targeted delivery to solid tumors and high-resolution molecular imaging. With the convergence and development of protein engineering, chemical biology, and nanotechnology, multifunctional molecular tools based on affibodies will continue to emerge, propelling precision medicine to new heights.

Based on phage display and yeast display technologies, TekBiotech (Tianjin) Co., Ltd. has established a comprehensive affinity protein development service. The company offers one-stop services ranging from the construction and screening of affinity-matured libraries to downstream synthesis and activity validation (including molecular-level affinity validation, cellular-level validation, and animal model validation), providing robust technical support for clients’ research projects.

References:

[1] Frejd, F., Kim, KT. Affibody molecules as engineered protein drugs. Exp Mol Med 49, e306 (2017).

[2] Wang, H., Wei, L., Du, C., Kam, A., & Loo, S. Recent Progress on Affibody-Based Supramolecular Architectures: Moving from Monomeric Constructs to Multivalent Assemblies. Pharmaceuticals 2025, 18, 1669

[3] The many virtues of staphylococcal protein A: A journey from N to C terminus. Journal of Biotechnology 2025, 406, 272-280.

[4] Zhang H, Zheng M, Cai Y, Kamara S, Chen J, Zhu S, Zhang L. Novel affibody molecules targeting the AXL extracellular structural domain for molecular imaging and targeted therapy of gastric cancer. Gastric Cancer. 2025 Mar;28(2):174-186.

Previous:DGCR2-Targeting Affibody Molecules for Beta-Cell Drug Delivery and Imaging Reagent Development Next:None!